Use of mass spectrometry to assess plasma stability of Antibody Drug Conjugates
ADCs represent complex biologics combing a targeting antibody molecule with a cytotoxic warhead via a linker system. The design of the linker systems is crucial to ensure the warhead is only released at the target site, whilst enabling conjugation to an active site on the protein.
Mass spectrometry can be utilized in various modalities to monitor loss of payloads when incubated in plasma providing a rapid measurement of relative stability.
This webinar will detail how mass spectrometry is used in ADC development and how the X500B QTOF system represents a versatile platform for measurement of intact, reduced, and digested proteins.
Attend this webinar to:
- Understand how LC-MS can be used to study the stability of an ADC in plasma
- Find out how LC-MS can be used to calculate the antibody drug ratio of an intact ADC
- Discover how LC-MS has been used to study the payload release of an ADC
Presenter: Chris Nortcliffe (Mass Spectrometry Manager | Sterling Pharma Solutions | UK)
Dr Christopher Nortcliffe is the mass spectrometry manager in the UK at Sterling Pharma Solutions, a CDMO pharmaceutical partner company. He has a background in protein and DNA analysis, obtaining his PhD from the University of Manchester on studying noncovalent interactions by mass spectrometry in 2016. After Manchester, Christopher worked for SCIEX as a specialist in LC-MS analysis of biologics before moving to Sterling Pharma Solutions, where he manages the LC-MS service and is an expert in the LC-MS analysis of biotherapeutics and ADCs.
